Breaking News
June 18, 2018 - AHA: Family Perseveres After Losing Father to Heart Attack
June 18, 2018 - Oral propranolol seems safe for infantile hemangioma
June 18, 2018 - New study gives explanation for food’s prominence in memory
June 18, 2018 - First photoactive drug to fight Parkinson’s disease
June 18, 2018 - Patient’s self-evaluation of personality disorders not as far off as previously perceived
June 18, 2018 - Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis
June 18, 2018 - Vitamin B3 has a positive effect on damaged nerve cells in Parkinson’s patients
June 17, 2018 - Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)
June 17, 2018 - Bid to beat obesity focuses on fat that keeps us warm
June 17, 2018 - Work Stress May Increase Risk of Developing Atrial Fibrillation
June 17, 2018 - New Zealand’s secret recipe for active school travel: The neighborhood built environment
June 17, 2018 - New Medscape report reveals sexual harassment rate of physicians
June 17, 2018 - Surgical Blood Transfusions Tied to Clot Risk
June 17, 2018 - CDC chief makes $375K, far exceeding his predecessors’ pay
June 17, 2018 - Education linked to higher risk of short-sightedness
June 17, 2018 - Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial
June 17, 2018 - UA registers a more customised multifocal lens to correct presbyopia
June 17, 2018 - U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
June 17, 2018 - Vaginal estrogen tablets, moisturizers and placebo gel all can improve vaginal discomfort
June 17, 2018 - Addition of Bezafibrate Beneficial in Primary Biliary Cholangitis
June 17, 2018 - Radiation Therapy for Cancer – National Cancer Institute
June 17, 2018 - Technology could help pregnant women detect health complications
June 17, 2018 - Study finds drop in frequent use of ED after Affordable Care Act
June 17, 2018 - Do Antipsychotic Meds for Kids Raise Diabetes Risk?
June 17, 2018 - New light shed on mechanisms of paediatric epilepsy
June 17, 2018 - People who deeply grasp the pain or happiness of others also process music differently in the brain
June 16, 2018 - Scientists discover how cancer-targeting ‘Natural Killer’ cells are fueled in the body
June 16, 2018 - New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma
June 16, 2018 - Annual Report to the Nation: overall cancer mortality continues to decline, prostate cancer mortality has stabilized
June 16, 2018 - Ibuprofen, acetaminophen more effective than opioids in treating dental pain
June 16, 2018 - Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia
June 16, 2018 - Price competition for generic drugs linked to increase in manufacturing-related recalls
June 16, 2018 - Researchers develop biomimetic nanosystem to deliver therapeutic proteins to target tumors
June 16, 2018 - Negative Pressure Wound Tx No Benefit for Lower Limb Open Fx
June 16, 2018 - Should I Get Screened for Prostate Cancer?
June 16, 2018 - Biochemist, physicist team to see antibacterial TCS deform mitochondria
June 16, 2018 - New 2D Superresolution mode for ZEISS Airyscan offers higher resolution in live cell imaging
June 16, 2018 - Money Spurs Those With Heart Disease to Step Lively
June 16, 2018 - Lower Dose of Prostate Cancer Drug with Food
June 16, 2018 - New findings demonstrate how the food we eat affects biochemical signals in the gut
June 16, 2018 - Scientists develop method to determine metabolic activity of neural networks
June 16, 2018 - Topical gel may lower breast cancer risk in women with dense breast tissue
June 16, 2018 - Research team diagnoses asthma with nasal brush test
June 16, 2018 - Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations
June 16, 2018 - Novel PET imaging noninvasively pinpoints colitis inflammation
June 16, 2018 - New clinical trial of MS drug will be first to recognize needs of wheelchair users
June 16, 2018 - Evoke Announces FDA Submission of New Drug Application for Gimoti
June 16, 2018 - New study links gray hair with immune system activity and viral infection
June 16, 2018 - Various E-cigarette flavorings may increase risk of cardiovascular disease
June 16, 2018 - Research sheds light on pathways involved in transmitting itch sensations from skin to brain
June 16, 2018 - Eminent biologist resigns over allegations of gender discrimination and sexual harassment
June 16, 2018 - Consuming sugary soft drinks can make you fat
June 16, 2018 - CDC: Preterm Births Increased in United States During 2014-2016
June 16, 2018 - Adolescents with hay fever have higher rates of anxiety and depression, lower resistance to stress
June 16, 2018 - Metabolic process providing energy to heart muscle fails to mature in babies with hypertrophy
June 16, 2018 - TU Graz researchers manipulate enzymes to build ring-shaped molecular structures
June 16, 2018 - Looking Good! Plastic Surgery for Men Surges
June 16, 2018 - Discovery of how HIV hedges its bets opens the door to new therapies
June 15, 2018 - Researchers evaluate left ventricular systolic function after pulmonary valve replacement
June 15, 2018 - New resource launched based on first-hand experiences of premature baby loss
June 15, 2018 - About Teen Pregnancy | Teen Pregnancy | Reproductive Health
June 15, 2018 - In southern Mozambique, one out of three people diagnosed with HIV do not disclose their status
June 15, 2018 - Researchers discover genomic characteristics that define testicular germ cell cancer
June 15, 2018 - Engineers create first 3D computer model to show breast duct development
June 15, 2018 - ANU scientists invent new system that could help crack down on illegal drug trade
June 15, 2018 - Study shows remarkable plasticity of the brain in finding work-arounds after catastrophic injuries
June 15, 2018 - Study finds higher response to anti-PD1 immunotherapy in older melanoma patients
June 15, 2018 - New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients
June 15, 2018 - Smoking, lack of exercise linked to early death after divorce
June 15, 2018 - Researchers identify gene enhancer that affects sex determination
June 15, 2018 - New collaboration integrates Intabio’s Blaze solution with Bruker’s mass spectrometers
June 15, 2018 - Blood samples can be used to uncover genetic secrets inside the brain
June 15, 2018 - Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA
June 15, 2018 - Can you rely on the drugs that your doctor prescribes?
June 15, 2018 - WHO: Paraguay achieves malaria-free status
June 15, 2018 - Investigating Enamel Nanostructure with Nanoindentation
June 15, 2018 - FDA Approves Moxidectin for the Treatment of River Blindness
June 15, 2018 - Researchers discover cell structure that plays a role in epigenetic inheritance
June 15, 2018 - Study shows how using service dogs may provide physiological benefits to veterans with PTSD
June 15, 2018 - New chemical solution could reduce chances of infection associated with root canal work
Pfizer Announces FDA Approval of Xeljanz (tofacitinib) and Xeljanz XR for the Treatment of Active Psoriatic Arthritis

Pfizer Announces FDA Approval of Xeljanz (tofacitinib) and Xeljanz XR for the Treatment of Active Psoriatic Arthritis

image_pdfDownload PDFimage_print

December 14, 2017 – Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has approved Xeljanz 5 mg twice daily (BID) and Xeljanz XR (tofacitinib) extended release 11 mg once daily (QD) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). Xeljanz/Xeljanz XR is the first and only Janus kinase (JAK) inhibitor approved by the FDA for both moderate to severe rheumatoid arthritis (RA) and active PsA.

“Psoriatic arthritis is a complex and progressive disease with an unpredictable course,” said Angela Hwang, Global President, Inflammation and Immunology, Pfizer. “The approval of Xeljanz is an important step forward for patients seeking new treatments and is a testament to Pfizer’s unwavering commitment to advancing patient care.”

The recommended dose of Xeljanz/Xeljanz XR is in combination with nonbiologic DMARDs, and use in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

The FDA approval of Xeljanz for the treatment of adult patients with active PsA was based on data from the Phase 3 Oral Psoriatic Arthritis Trial (OPAL) clinical development program, which consisted of two pivotal studies, OPAL Broaden and OPAL Beyond, as well as available data from an ongoing long-term extension trial, OPAL Balance. The findings from OPAL Broaden and OPAL Beyond were published in October 2017 in the New England Journal of Medicine.

Both pivotal studies met their two primary efficacy endpoints, demonstrating statistically significant improvements in American College of Rheumatology 20 (ACR20) response and change from baseline in the Health Assessment Questionnaire–Disability Index (HAQ-DI) score at three months in patients receiving Xeljanz 5 mg BID treatment in combination with a nonbiologic DMARD, compared to those treated with placebo. In OPAL Broaden, 50% of patients taking Xeljanz 5 mg BID achieved an ACR20 response, compared to 33% of patients taking placebo (p≤0.05), at three months. In OPAL Beyond, 50% of patients achieved an ACR20 response with Xeljanz 5 mg BID, compared to 24% of patients taking placebo (p≤0.05), at three months. In both studies, statistically significant improvements in ACR20 response was also seen with Xeljanz 5 mg BID compared to placebo at week 2, a secondary endpoint and the first post-baseline assessment (OPAL Broaden: 22% and 6% [p=0.0003], respectively; OPAL Beyond: 27% and 13% [p=0.0046], respectively).

“As a practicing rheumatologist, I’ve seen the significant physical impact psoriatic arthritis has on people living with the disease, and many patients are looking for additional therapeutic options,” said Philip Mease, M.D., Swedish Medical Center, University of Washington and study investigator. “I’m pleased that Xeljanz is now available for use in the treatment of this chronic condition.”

The safety profile observed in patients with active psoriatic arthritis treated with Xeljanz was consistent with the safety profile observed in rheumatoid arthritis patients. The most common adverse events observed occurring in greater than 3% of patients on Xeljanz 5 mg BID were nasopharyngitis, upper respiratory tract infection, headache and diarrhea.

“Psoriatic arthritis is a serious and debilitating chronic illness that should be diagnosed and treated early,” said Randy Beranek, president and CEO, National Psoriasis Foundation. “As an organization that advocates for people living with psoriatic arthritis, we welcome the availability of new therapies for treating this disease.”

About the OPAL Clinical Development Program

OPAL Broaden was a 12-month study in adult patients with active PsA who had an inadequate response to nonbiologic DMARDs and who were tumor necrosis factor inhibitor (TNFi) naïve. The study included an active control arm of adalimumab 40 mg administered subcutaneously every two weeks; however, the study was not powered for non-inferiority or superiority comparisons between tofacitinib and adalimumab. OPAL Beyond was a six-month study of adult patients with active PsA who had an inadequate response to a TNFi. All patients had active PsA for at least six months based upon the Classification Criteria for Psoriatic Arthritis (CASPAR), at least three tender/painful joints and at least three swollen joints, and active plaque psoriasis. In both studies, all patients were required to receive a stable background dose of a single nonbiologic DMARD.

About Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic, autoimmune, inflammatory disease that may include manifestations in peripheral joints, tendons, ligaments or skin. PsA may include a variety of symptoms such as joint pain and stiffness, swollen toes and/or fingers and reduced range of motion.

Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

DISCLOSURE NOTICE: The information contained in this release is as of December 14, 2017. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about XELJANZ and XELJANZ XR and a new indication for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including, without limitation, the ability to meet anticipated trial commencement and completion dates and regulatory submission dates, as well as the possibility of unfavorable clinical trial results, including unfavorable new clinical data and additional analyses of existing clinical data; uncertainties regarding the commercial success of XELJANZ and XELJANZ XR, including in the new indication; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any other applications for the new indication or any other potential indications for XELJANZ or XELJANZ XR may be filed with regulatory authorities in any jurisdictions; whether and when regulatory authorities in any jurisdictions may approve any other applications that may be filed or pending for XELJANZ or XELJANZ XR, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of XELJANZ and XELJANZ XR, including the new indication; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Source: Pfizer Inc.

Posted: December 2017

Related Articles:

Xeljanz (tofacitinib) FDA Approval History

Tagged with:

About author

Related Articles